ERCC1 and neoplasm: Low levels of ERCC1 expression were hypothesized to reflect decreased NER capacity and thus explain the increased tumor sensitivity to cisplatin-mediated DNA damage and improved clinical outcomes among cisplatin-treated bladder cancer patients.